AFFIMED NV (AFMD) Stock News
NASDAQ:AFMD - Nasdaq - NL0015001ZQ0 - Common Stock
AFMD Latest News and Analysis
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the...
Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company...
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
The combination of acimtamig with AlloNK® demonstrated an overall response rate of 86% and complete response of 55% in 22 heavily pretreated patients with...
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a...
Affimed Reports Third Quarter 2024 Financial Results & Business Update
Affimed Reports Third Quarter 2024 Financial Results & Business Update
AFM24 combination with atezolizumab: The non-small cell lung cancer (NSCLC) EGFR wild-type (EGFRwt) cohort completed enrollment: Objective response rate...
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
MANNHEIM, Germany, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients...
Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
MANNHEIM, Germany, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company...
Affimed to Present at the Cantor Global Healthcare Conference 2024
Affimed to Present at the Cantor Global Healthcare Conference 2024
MANNHEIM, Germany, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company...
Affimed Reports Second Quarter 2024 Financial Results & Business Update
Affimed Reports Second Quarter 2024 Financial Results & Business Update
AFM24 combination with atezolizumab: 24 patients treated in the EGFR mutant (EGFRmut) non-small cell lung cancer (NSCLC) cohort; in 17 response-evaluable...
Affimed Appoints Shawn M. Leland as Chief Executive Officer
Affimed Appoints Shawn M. Leland as Chief Executive Officer
MANNHEIM, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company...
Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
MANNHEIM, Germany, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients...
AFMD Stock Earnings: Affimed Beats EPS, Misses Revenue for Q1 2024
AFMD stock results show that Affimed beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Affimed Reports First Quarter 2024 Financial Results & Business Update
Affimed Reports First Quarter 2024 Financial Results & Business Update
- Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of 7 patients with complete response (CR) - -...
Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
MANNHEIM, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients...
Why Affimed Shares Are Soaring
Affimed shares are trading higher Monday after the company announced additional follow-up data from the on-going AFM24-102 study in non-small cell lung cancer (NSCLC).
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4...
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer ...
Affimed Announces Annual General Meeting of Shareholders
Affimed Announces Annual General Meeting of Shareholders
MANNHEIM, Germany, May 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company...
7 Penny Biotech Stocks to Triple Your Investment
Biotech penny stocks offer the chance to triple your investments and require an appetite for risk in order to capture returns.